Amaris can undertake the following Bioavailability/Bioequivalence studies
For certain classes of drugs like cytotoxic and psychotropic drugs, BE studies can be done only on appropriate patients.
An endpoint is the outcome that researcher’s measure during a clinical trial in order to determine whether or not an experimental therapy is effective. Researchers select endpoints based on clinical trial design, the nature of the condition being treated, and the anticipated effect of the drug being tested. In some cases of generic drugs, the bioavailability cannot be demonstrated using conventional PK/PD studies.
No matter what stage of Clinical Trials you are, we can help you. Amaris with the help of elaborate Investigator network across various therapeutic segments, experienced and insightful Project Management Team, established mechanisms for Site Management, Clinical Data Management, Clinical Trial Management, Medical Writing, Quality Assurance service, Training and Regulatory Liaison activities can provide effective Clinical Trial services to its clients. With a strong investigator network across the globe, Amaris Clinical is forging ahead as a reliable service provider in this segment. We provide the following expert service for drug development process: